100304-88-9

Basic information

• Product Name: 2-Acetamido-5-fluoropyridine
• Synonyms: 2-ACETAMIDO-5-FLUOROPYRIDINE;2-Acetamide-5-fluoropyridine;N-(5-Fluoropyridin-2-yl)acetamide;2-Acetamido-5-fluoropyridine ,97%;ethyl 6-chloro-2-(2,4-difluorophenyl)nicotinate;N-(5-Fluoro-2-pyridinyl)-acetamide;Acetamide, N-(5-fluoro-2-pyridinyl)-
• CAS NO: 100304-88-9
• Molecular Formula: C₇H₇FN₂O
• Molecular Weight: 154.14
• Product Categories: Pyridine;Pyridines
• Mol File: 100304-88-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 319.9 °C at 760 mmHg
• Flash Point: 147.3 °C
• Appearance: Colorless transparent liquid
• Density: 1.285 g/cm³
• Refractive Index: 1.556
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Acetamido-5-fluoropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Acetamido-5-fluoropyridine(100304-88-9)
• EPA Substance Registry System: 2-Acetamido-5-fluoropyridine(100304-88-9)

Safety Data

• Statements: 20/21/22
• Safety Statements: 3/7/9-36/37
• Hazardous Substances Data: 100304-88-9(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C7H7FN2O/c1-5(11)10-7-3-2-6(8)4-9-7/h2-4H,1H3,(H,9,10,11)

Upstream product

• 21717-96-4 2-amino-5-fluoropyridine 
• 75-36-5 acetyl chloride 
• 127773-43-7 Difluoroboryl N-(5-fluoro-2-pyridyl)acetamidate 

Downstream Products

• 21717-96-4 2-amino-5-fluoropyridine 

Relevant articles and documents

Inhibition of colitis by ring-modified analogues of 6-acetamido-2,4,5-trimethylpyridin-3-ol

6-Aminopyridin-3-ol scaffold has shown an excellent anti-inflammatory bowel disease activity. Various analogues with the scaffold were synthesized in pursuit of the diversity of side chains tethering on the C(6)-position. Structure-activity relationship among the analogues was investigated to understand the effects of the side chains and their linkers on their anti-inflammatory activities. In this study, structural modification moved beyond side chains on the C(6)-position and reached to pyridine ring itself. It expedited us to synthesize diverse ring-modified analogues of a representative pyridine-3-ol, 6-acetamido-2,4,5-trimethylpyridin-3-ol (9). In the evaluation of compounds on their inhibitory actions against TNF-α-induced adhesion of monocytic cells to colonic epithelial cells, an in vitro model mimicking colon inflammation, the effects of compounds 9, 17, and 19 were greater than tofacitinib, an orally available anti-colitis drug, and compound 17 showed the greatest activity. In addition, TNF-α-induced angiogenesis, which permits more inflammatory cell migration into inflamed tissues, was significantly blocked by compounds 17 and 19 in a concentration-dependent manner. In the comparison of in vivo therapeutic effects of compounds 9, 17, and 19 on dextran sulfate sodium (DSS)-induced colitis in mice, compound 17 was the most potent and efficacious, and compound 19 was better than compound 9 which showed a similar degree of inhibitory effect to tofacitinib. Taken together, it seems that either the trimethyl system or the hydroxyl group on the pyridinol ring is essential to the activity. This finding might become a new milestone in the development of pyridinol-based anti-inflammatory bowel disease agents.